Clinical dataset of GPC3-targeted CAR-T cell therapy (C-CAR031) in patients with advanced hepatocellular carcinoma

All patients were pathologically diagnosed with HCC, predominantly with BCLC stage B or C. Data were collected from treatment initiation to the end of follow‑up, covering baseline characteristics, tumor biological markers, treatment responses, and survival outcomes.Dataset variables include:Demographics and baseline characteristics: sex, ageTumor stage and liver function: BCLC stage, ECOG performance status (0/1), Child‑Pugh scoreViral hepatitis and cirrhosis: Hepatitis B status, Hepatitis C status, presence of cirrhosisTumor markers and burden: Serum alpha‑fetoprotein (AFP, ng/ml), presence of intrahepatic/extrahepatic lesions, sum of diameters of target lesions (mm)GPC3 expression (immunohistochemistry): biopsy site, overall GPC3 positivity (%), membrane GPC3 positivity (%), GPC3 H‑scorePrior treatment and response: number of prior lines of therapy, best response (according to RECIST: PR/SD/PD/NE)Survival data: duration of response (Dor) event and time (months), progression‑free survival (PFS) event and time (months), overall survival (OS) event and time (months)The “Annotation” worksheet provides clear definitions and coding explanations for each variable, facilitating data reproducibility and secondary analysis.

This dataset can be used to evaluate the association between GPC3 expression levels and the efficacy/prognosis of CAR‑T therapy, as well as to support biomarker research and survival modeling in immunotherapy for liver cancer.